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I. Literature Review
I. Disease Burden of neglected tropical diseases or NTD’s
The burden of neglected tropical diseases or NTDs is greater than that of malaria, tuberculosis,
and other diseases such as HIV/AIDS (Hotez 2011) .One billion of the 2.7 billion poorest people
living on less than $2 US dollars a day are infected by one or more neglected tropical diseases,
which intensify poverty and stigmatize those that are affected (Liese, Rosenberg et al. 2010).
NTDs which often overlap geographically, predominantly affect poor populations living in rural
tropical and subtropical regions. According to the WHO 2010 report on NTDs, “100% of lowincome countries are affected by at least five neglected tropical diseases simultaneously”(WHO
2010). NTDs contribute not only to a high morbidity and disability, but also contribute to an
ongoing cycle of poverty and shame for the people they affect (Hotez 2011).

According to a 2002 report by the World Health Organization (WHO), neglected tropical
diseases, which include soil transmitted helminths (STH), trachoma, schistosomiasis,
onchoceraisis, and lymphatic filariasis (LF), contribute to 5% of the global burden of infectious
diseases (Smits 2009). The world’s highest prevalent NTDs which include hookworm, ascaris,
trichuris, lymphatic filariasis, schistosomiasis, trachoma and onchocerciasis infect over 1 billion
people globally and contribute to 52.1 million disability-adjusted life years (DALYs) (Fenwick
2012). The burden of disease caused by NTDs may be under estimated due to the fact that they
may be chronic or that the proper diagnostic tools or epidemiology to estimate the true burden of
disease are lacking (Smits 2009). The chronic disease caused by the NTDs can result in
disfigurement, impaired child development, poor pregnancy outcomes, and reduced productivity
(Hotez, Molyneux et al. 2007).
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In 2010, the World Health Organization published its first report on neglected tropical
diseases which stated that the highest prevalence NTDs could be eliminated by 2020 (WHO
2010) . Strategies to battle NTDS include increased hygiene, environmental improvement,
vector control, sustained socio economic development, and preventive chemotherapy(Smits
2009). Preventive chemotherapy through targeted mass drug administration is one of the most
“tool ready” and cost-effective methods for controlling NTDs. The donation of drugs or
availability of drugs at very low costs from pharmaceutical companies has made the mass drug
administration for control of NTDs possible, even in resource poor countries. According to the
WHO 2012 report on the roadmap for reducing the impact of global NTDs, short term solutions
such as preventative chemotherapy can significantly reduce morbidity and transmission (WHO
2012). However, long term elimination will not be possible without access to clean water,
sanitation, and improved living conditions (WHO 2012). The WHO and United States Agency
for International Development or USAID have established elimination and control goals for
NTDs targeted by mass drug administration or MDAs. LF is targeted for elimination by 2020.
Onchocerciais is targeted for elimination in the Americas by 2016. In addition, the WHO would
like to reduce the prevalence of NTDs by 50% in 70% of the population living in areas endemic
for these diseases (Hotez 2011).

II. Overview of the major NTDs
A. Trachoma
Trachoma is the leading infectious cause of blindness worldwide (Burton 2007). Trachoma is
caused by the bacterium Chlamydia trachomatis and can cause visual impairment and blindness
(Hu, Harding-Esch et al. 2010). Trachoma infection has been observed for centuries in all areas
15

of the world including Europe and North America, but today it is found predominantly in poor
countries in sub-Saharan Africa and Asia (Hu, Harding-Esch et al. 2010). Trachoma is estimated
to cause 2.3-4.0 million DALYs (Smits 2009). Trachoma is transmitted by flies. Repeated
infection of the ocular surface initiates chronic inflammatory responses that lead to cornea
damage and scarring(Feasey, Wansbrough-Jones et al. 2010). As the scar tissue shortens, the eye
lids are distorted and it causes the eyelashes to come into contact with the surface of the eye
(trichiasis). When trichiasis occurs the cornea is compromised and blindness occurs(Burton
2007).
MDA for trachoma is a 20mg/kg dose of azithromycin. Other methods of controlling trachoma
include improved sanitation, facial hygiene, and health education. One way to undo the effects of
the blindness caused by trachoma is through eyelid surgery which reverses the in-turning of the
eyelashes and may also improve non-visual symptoms (Mathew, Turner et al. 2009). Through
the WHO established Alliance for the Global Elimination of Blinding Trachoma, trachoma
control is implemented through the SAFE Strategy (WEST 2003). The components of the SAFE
strategy include both short term and long term interventions for control and prevention of
trachoma and trichiasis: S, surgery for trichiasis, A, antibiotics to prevent infection, F, facial
cleanliness, and E, environmental improvement. The WHO has targeted the elimination of
blinding trachoma for the year 2020. Treatment for trachoma is a single oral dose of the
antibiotic azithromyxin with treatment every 6-12 months (Mathew, Turner et al. 2009).
B. Soil Transmitted Helminths (STH)
Soil transmitted helminthiasis (STH) is caused primarily by the nematodes Ascaris lumbricoides
(roundworm), Ancylostoma duodenale, Necator americanus (hookworm), and Trichuris
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trichiura (whipworm) which infect the intestine (Bethony, Brooker et al. 2006). Poor personal
hygiene and sanitation contribute to the transmission of STH (Bethony, Brooker et al. 2006).
Global prevalence of ascariasis, hookworm, and trichriasis is 600 million(Smits 2009). It is
estimated that the burden of STH ranges from 4.7-39 million DALYS (Smits 2009). STH are
transmitted through contaminated soil or consuming fruits and vegetables that haven’t been fully
cooked, washed or peeled. After the worms are acquired through ingestion or the soil, they infect
the gastro-intestinal tract, reproduce, and release eggs into the environment through the
feces(Feasey, Wansbrough-Jones et al. 2010). Children infected from STH can suffer from
anemia, vitamin A deficiency, impaired growth, malnutrition, and reduced cognitive
development (WHO 2010). The main approach to achieve control or elimination of the highly
prevalent STH’s includes MDA with albendazole or mebendazole together with
ivermectin(Hotez 2011).
C. Schistosomiasis
Schistosomisasis or bilharziasis is caused by the trematodes, Schistosoma haematobium,
Schistosoma mansoni, Schistosoma japonica, and Schistosoma mekongi(WHO 2010).
Schistosomiasis is common in places with poor sanitation and is acquired by swimming, bathing
or coming into contact with contaminated fresh water (Steinmann, Keiser et al. 2006). Fresh
water snails carry the larval form (schistosomes) of the trematodes which can penetrate human
skin (Feasey, Wansbrough-Jones et al. 2010). The disease burden of schistosomiasis is estimated
to be 1.8-4.5 million DALYs (Smits 2009). It is estimated that nearly 600 million people suffer
from schistosomiasis with 90% in Africa (Hotez 2011). In Africa, having schistosomasis has
been reported to increase the likelihood of contracting HIV/AIDS and nearly 300,000 people die
of schistosomiasis each year(Hotez and Fenwick 2009). The symptoms of schistosomiasis are
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not caused by the worms themselves, but by the body’s reaction to the eggs as they pass through
blood vessels, intestine, ureters, bladder or become lodged in the liver or lungs(Feasey,
Wansbrough-Jones et al. 2010). The eggs can cause chronic ill health and can damage major
organs including the liver, intestine, spleen, lungs, and bladder (Ross, Bartley et al. 2002).
School aged children are most at risk for schistosomiasis. Children who are repeatedly infected
by shistosomes can develop anemia, malnutrition, and impaired cognitive development which
can affect school attendance(WHO 2010). Schistosomiasis treatment and elimination strategies
include treatment with Praziquantel based on body weight or height as well as improved access
to clean water and sanitation (Smits 2009).
D. Onchoceriasis
Onchoceriasis more commonly known as river blindness, is caused by the nematode worm
Onchocerca volvus (Duke 1990). The WHO estimates that 37 million people are infected with
O. volvulus worldwide; of these people 270,000 are blind and 500,000 have some sort of visual
impairment. Onchoceriasis causes nearly 1 million DALYs (Boatin and Richards Jr 2006).
Transmission of onchoceriasis occurs from multiple bites from the Simuliaum black fly which
breeds near fast running streams and rivers. People most at risk for onchocerciasis include
fishermen, farmers, or those that spend long hours or live near the black fly breeding sites. In
fact, in areas near rivers where the disease exists almost every person in a community may be
infected and almost half of the population will suffer from blindness (Etya'al 2001). Symptoms
of the disease do not manifest until one to three years after the parasite has been injected into its
victim (Etya'al 2001). The adult worm lives in the fibrous and subcutaneious nodules. The adult
females produce millions microfilariae which migrate under the skin and to the eyes(Crompton
and WHO 2006).
18

Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan ®, Merck &
Co., Inc.) through the Mectizan Donation Programme (MDP).(Boatin and Richards Jr 2006).
Unfortunately ivermectin does not kill the adult but only the larvae, so treatment must be
continued for the life of the adult worm which can be as long as 15 years (Amazigo, Leak et al.
2012). International programs including ,the African Program for Onchocerciasis control
(APOC) , the Onchocerciasis Control Programme of West Africa, and the Onchocerciasis
Elimination Program for the Americas have been successful with implementation of larvicide
spraying for black fly control and mass drug administration of ivermectin (Richards, Boatin et al.
2001). Interruption of Transmission of Oncocerciasis has been documented in endemic areas of
Guatemala, and several regions in Mali and Senegal (Feasey, Wansbrough-Jones et al. 2010).
E. Lymphatic filariasis (LF)
Lymphatic filariasis also known as elephantiasis is a parasitic infection caused by Wuchereria
bancrofti, Brugia malai, and Brugia timori. LF has no animal reservoir and is transmitted by
mosquitoes. The main symptoms of LF include swelling of the limbs or lymphodema,
elephantiasis, and swelling of genital organs or hydrocele (Richards, Eigege et al. 2011). LF is
estimated to have a disease burden 5.6-5.8 DALYS per million people. It is estimated that 1.2
billion people live in areas endemic for LF(Crompton and WHO 2006). Three drugs are
recommended for the treatment of LF, ivermectin, diethlcarbamazine (DEC), and albendazole.
Adult worms are not totally eliminated by one drug treatment, so a combination of drugs is
required. The strategy to eliminate lymphatic filariasis has two components with one component
being MDA of DEC+ albendazole or ivermectin+ albendazole. The other component involves
home-based care and community based programs to guide individuals suffering from the disease
and educate persons on hygiene and treatment of affected limbs (Crompton and WHO 2006). In
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order to reduce transmission of LF, it is recommended to have a coverage of 70-80% over a
period of 5-6 years (Ottesen, Hooper et al. 2008).

In the year 2000, the WHO established the

Global Program to Eliminate Lymphatic Filariais (GPELF). Through MDA, 1.9 billion
treatments to people in 48 countries have been delivered. Between 2000-2008, the GPELF has
prevented more than 6 million cases of hydrocele ,4 million cases of lymphodema, and 6 million
DALYs have been averted(Ottesen, Hooper et al. 2008).
III. Preventive chemotherapy as a strategy to control or eliminate NTDs.
According to the WHO, nearly 90% of NTDs can be treated with drugs that only need to be
administered once or twice each year in contrast to diseases like AIDS, and TB (WHO 2012).
Large scale chemotherapy is a cost-effective intervention that contributes to several Millennium
Development goals outlined by the United Nations including, eradicating poverty and hunger,
achieving universal primary education, promoting gender equality, reducing childhood mortality,
improving maternal health, and fighting HIV/AIDS, TB, and malaria(Crompton and WHO
2006). Preventative chemotherapy (PCT) is “the regular, large-scale elimination of drugs—either
alone or in combination—to entire population groups living in areas where helminth infections
and trachoma are prevalent, with the aim of reducing their morbidity and
transmission”(Montresor, Gabrielli et al. 2012). The WHO recommends preventative
chemotherapy as a strategy for the control of highly prevalent NTDs including lymphatic
filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and
trachoma(Crompton and WHO 2006). Preventative chemotherapy can be targeted based on the
epidemiology of a disease in a particular area or can be applied to an entire population in an
endemic area using mass drug administration or MDA (Crompton and WHO 2006). Treatment
and frequency of the MDA depends on endemicity of a disease in a particular area. Integrated
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preventative chemotherapy is a new, key strategy for battling areas where more than one NTD is
endemic. Coordinated implementation of preventative chemotherapy for LF, onchocerciasis,
schistosomiasis, STH, and trachoma helps to attain higher coverage rates and to efficiently use
resources(Montresor, Gabrielli et al. 2012).
Large scale preventative chemotherapy is made possible by the donation or availability of drugs
at low cost by pharmaceutical companies. Albendazole is donated by GlaxoSmithKline.
Ivermectin (Mectizan®) and praziquantel are donated by Merck. Albendazole and ivermectin are
available as long as necessary until the elimination program reaches success. Mebendazole is
donated by Johnson and Johnson. Azithromycin (Zithromax ®) used to treat Trachoma, is
donated by Pfizer. In order to assess the performance of large scale chemotherapy it is important
to determine the coverage of the MDA. Coverage refers to the proportion of the persons in the
target population who took the recommended drugs (Crompton and WHO 2006). Determining
coverage is critical to assess the effectiveness of the MDA (Smits 2009). Low coverage
threatens the success of MDA programs and may present a risk for the development of drug
resistance(Smits 2009). Health education and community participation are critical for achieving
high coverage rates and the success of the MDA programs (Smits 2009).
IV. Current PCT and MDA programs
Progress has been made in the last 10 years to scale up NTD control and public health
partnerships between governments, NGOs, and pharmaceutical companies, (Montresor, Gabrielli
et al. 2012). It is estimated that over 700 million individuals are being treated for one or more
NTDs each year(Montresor, Gabrielli et al. 2012). A summary of MDA programs,
pharmaceutical partners, and number of people treated are listed in table 1. After many
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successful rounds of preventative chemotherapy onchoceriasis is on track for elimination in the
Americas. For exam ample in Guatemala researchers have observed the disruption of
onchocerciasis transmission and children between 6-12 years of age living in endemic areas had
no serological evidence of infection(Cruz-Ortiz, Gonzalez et al. 2012). In 2011, Columbia
became the first country in the Americas to successfully eliminated onchocerciasis and is on
track for elimination in Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela
(Gustavsen, Hopkins et al. 2011). Globally, progress has been made in the last 10 years to scale
up NTD control through public health partnerships between governments, non-governmental
organizations (NGOs), and pharmaceutical companies. It is estimated that over 700 million
people are being treated for one or more NTDs each year (WHO 2010). For instance an
estimated 22 million people have been protected from LF infection and disease saving an
estimated $24.2 billion US dollars (Addiss and Filariasis 2010).
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Table 1: Summary of programs for NTDs Adapted from Montressor et al. 2012 and Smitts 2009,
Fenwick 2012

Onchocerciasis

Disease

International Trachoma
Initiative

Mectizan® (Ivermectin)
Donation Program,
African programme for
onchocerciasis control
(APOC) and the
Onchocerciasis
elimination Program for
the Americas (OEPA).

Program or Initiative

albendazole or
mebendazole

azithromycin

Ivermectin

Treatment

Johnson and
Johnson,
GlaxoSmithKline

Pfizer

Merck

Pharmaceutical
partner(s)

78

112

42

33

21

50

26

33

385,270,000(28%)

19,570,000(8%)

Number of people
receiving treatment Frequency of
in 2009 (coverage
intervention
%)

Trachoma
2001 World Health
Assembly resolultion,
Children without worms

Medpharm/Merck

53

Countries where
Endemic
large scale MDA is
countries (n)
being implemented

Soil Transmitted
Helminthiasis

praziquantel

81

annually

68,730,261 (57%) annually
annually for
school aged
45,000,000 (13%) children
once or twice a
year depending
on prevalence
109,749,000 (40%) of infection
According to
prevalence of
infection

Diethylcarbamazide
(DEC), or Ivermectin
plus Albendazole
Merck, EISAI

Schistosomiasis

Schistosomiasis Control
Initiative
Global Alliance to
Elliminate Lymphatic
Filariasis (GAELF),
Mectizan® (Ivermectin)
Donation Program

Lymphatic
filariasis
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V. History of Preventative Chemotherapy in Cameroon
The health system in Cameroon is organized into central, regional and into 179 smaller local
health districts (Tchuem Tchuenté, Kamwa Ngassam et al. 2012). The population density in
Cameroon varies greatly from region to region and can range from 7.4 inhabitants/km2 to 141.5
inhabitants/km2(Tchuem Tchuenté, Kamwa Ngassam et al. 2012).
Cameroon has a high prevalence onchocerciasis, lymphatic filariasis, schistosomiasis, trachoma
and soil transmitted helminiths and affect millions of people throughout the country(Klopp
2009). According to Helen Keller International, a partner working with the Cameroon Ministry
of Health , over10 million people are at risk for onchocerciasis, 5 million are at risk for
schistosomiasis, and 2 million people may already be infected with schistosomiasis (Klopp
2009). In south west Cameroon, the prevalence of STH infections ranged from 30-40%
depending on if person lives in an urban or rural area (Mbuh, Ntonifor et al. 2012).
In Cameroon, the National Strategic Plan for the control of STH and schistosomiasis began in
2004 with a limited budget and under a small scale(Tchuem Tchuenté, Kamwa Ngassam et al.
2012). In 2007, with the help of international and national partners including the Cameroon
Ministry of Health, Helen Keller International, United States Agency for International
Development, Children Without Worms, Mectizan® Donation program, and African Program
for Onocerciasis Control and other partners, the program was implemented all over the country.
De-worming campaigns targeting school aged children have occurred annually since
2007(Tchuem Tchuenté, Kamwa Ngassam et al. 2012). In 2009, the Government of Cameroon
implemented an integrated approach for controlling NTDs for greater efficiency and costeffectiveness(Tchuente and N'Goran 2009). With monetary support from the United States
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Agency for International Development (USAID), the Cameroon government coordinates coadministration of several drugs for control of NTDs including lymphatic filariasis,
onchoceriasis, trachoma, schistosomiasis and soil transmitted helminths(Tchuem Tchuenté,
Kamwa Ngassam et al. 2012).
One item to be concerned about while implementing PCT in Cameroon is the occurrence of Lao
Lao, a filarial nematode, in areas also endemic for LF, onchoccerciasis, schistosomiasis, and
STH. When persons have high levels of loiasis, Ivemectin treatment can result in severe adverse
reactions events which could include encephalopathy(Crompton and WHO 2006).
Recent mapping campaigns to determine the prevalence of STH and schistosomiasis have
demonstrated that the prevalence of STH and schistosomiasis has declined from 81.1-93% down
to 10.5%-46%, proving the impact of annual deworming and NTD control campaigns(Tchuem
Tchuenté, Kamwa Ngassam et al. 2012).
VI. Purpose of the Study
In order to accurately measure the achievement of mass drug administration programs and drug
delivery it is important to make sure that the drugs reach everyone that needs them and that the
coverage is high enough to interrupt transmission. It is believed that through adequate
chemotherapy to an at risk population will reduce the prevalence of infection and lead to
elimination (Worrell and Mathieu 2012). MDA programs rely mostly on reported drug coverage
calculated based on the number of doses given during the drug distribution and the denominator
is the targeted population(Worrell and Mathieu 2012). Another way to measure drug coverage is
through coverage surveys administered to households in the area where the MDA was
administered. Coverage surveys are important for validating the reported coverage and in
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addition, provide valuable information including basic demographics of the targeted population
and reasons for non-compliance (Worrell and Mathieu 2012). The WHO recommends
monitoring MDA programs through coverage surveys, however, coverage surveys require both
monetary and human resources that may be scarce in resource poor settings (Worrell and
Mathieu 2012). Validating the reported coverage through a coverage survey is an important
component of MDA program evaluation and monitoring(Worrell and Mathieu 2012).
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Abstract:

Health education and preventive chemotherapy are main strategies to control or eliminate
neglected tropical diseases (NTDs) such as lymphatic filariasis (LF), trachoma, onchocerciasis,
schistosomiasis (SCH), and soil-transmitted helminthiasis (STH). Integrated MDA for LF,
onchocerciasis, SCH, STH, and trachoma were organized in the Koza district of Cameroon from
July to August 2011. Ivermectin (IVM) and albendazole (ALB) were distributed for LF to the
entire population except pregnant or lactating women, children <90 cm in height, and the
severely ill. Azithromycin was distributed at least one week after the LF MDA to all persons
older than 6 months of age. Praziquantel (PZQ), targeting school age children (SAC), was only
distributed in schools. In order to validate reported coverage and assess the knowledge and
attitude of the population towards NTDs and MDAs, an independent coverage and Knowledge,
Attitudes, and Practice (KAP) survey was administered. The WHO recommended population
based 30-cluster coverage survey was implemented. Clusters were selected by Probability
Proportional to Estimated Size and in each cluster, 10 houses were selected using the improved

29

expanded program on immunization random walk. Coverage questions were administered by
trained interviewers to each person living in selected houses and KAP questions were asked to a
randomly selected adult in the house.
A total of 1303 persons participated in the coverage survey and 149 adults answered the KAP
questions. The survey coverage estimates for IVM /ALB and azithromycin are 76.9% (95% CI
72.0-81.9), 86.8% (95% CI 80.9-92.7), respectively, while the reported coverage is 80.3% and
93%, respectively. The survey coverage estimated for PZQ among SAC is 39.9% (95% CI 30.749.1), reported coverage is unknown. There was no significant association between participation
in the MDA and age, gender, or knowing the disease. SAC who attended school were 269 times
as likely to have taken PZQ and 3 times as likely to have taken LF drugs as SAC not attending
school. Less than 50% of respondents had heard of LF and only 31.8% could mention at least
one LF symptom. More than 70% of respondents had heard of STH, SCH, and trachoma, but
only 52.3%, 40%, 30%, respectively, knew at least one way to prevent or treat STH, SCH, and
trachoma. Despite low or incorrect knowledge of LF, SCH, STH, and trachoma, overall, MDA
coverage was good except for the PZQ which was only distributed in school.
Keywords: Mass Drug Administration, Neglected Tropical Diseases, Cameroon, Coverage,
Survey

Introduction:
The burden of neglected tropical diseases or NTDs is greater than that of malaria, tuberculosis,
and other diseases such as HIV/AIDS(Hotez 2011) . The world’s highest prevalent NTDs which
include hookworm, ascaris, trichuris, Lymphatic filariasis, schistosomiasis, trachoma and
onchocerciasis infect over 1 billion people globally and contribute to 52.1 million disability30

adjusted life years (DALYs) annually (Fenwick 2012). The chronic disease caused by the NTDs
can result in disfigurement, impaired child development, poor pregnancy outcomes, and reduced
productivity (Hotez, Molyneux et al. 2007). Preventive chemotherapy through targeted mass
drug administration is one of the most “tool ready” and cost-effective methods for controlling
NTDs. The donation of drugs or availability of drugs at very low costs from pharmaceutical
companies has made the mass drug administration for control of NTDs possible, even in resource
poor countries.
In Cameroon, the plan for control of STH and schistosomiasis began in 2004 with a limited
budget and under a small scale. In 2007, with the help of international and national partners, the
program was implemented all over the country. De-worming campaigns targeting school aged
children have occurred annually since 2007 (Tchuem Tchuenté, Kamwa Ngassam et al. 2012).
An integrated approach for controlling the most prevalent NTDs including not only STH and
schistosomiasis but LF, trachoma, and onchoceraisis was established in 2009 for greater
efficiency and cost-effectiveness (Tchuente and N'Goran 2009). In July-August 2011, a mass
drug administration (MDA) campaign was implemented in the Koza District of Cameroon, in the
extreme nord region. In order to validate reported coverage and assess the knowledge and
attitude of the population towards NTDs and MDAs, an independent coverage and Knowledge,
Attitudes, and Practice (KAP) survey was administered.

Methods
Mass drug administration for LF, onchocerciasis, schistosomiasis, STH and trachoma were
organized in the Koza district in July-August 2011. The Centers for Disease Control and
Prevention (CDC) and the Cameroon Ministry of Health implemented the standard WHO
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cluster-survey protocol in 8 of the 14 sub-districts of Koza District: Koza 1 and 2, Gaboua,
Ouval, Gouzda Wayam, Djingliya, M’tsikar, Ndougui Kilda .
MDA program consisted of a sub-district based distribution of single dose of 400 mg Ivermectin,
single dose 400 mg Albendazole, 20mg/kg azithromyxin. Praziquantel doses of 40mg/kg were
delivered in an annual primary school-based distribution.
Ivermectin and albendazole were distributed to the entire population except pregnant women,
lactating women in the first week after birth, children <90 cm in height, and the severely ill.
Azithromycin was distributed at least one week after the distribution of ivermectin and
albendazole to all persons above the age of 6 months. Praziquantal was only distributed in
schools to school aged children (SAC).
After the MDA, the districts were required to report coverage of each ivermectin/albendazole ,
Azithromycin, and praziquantel to the Ministry of Health. Reported coverage for the Koza
district for ivermectin/ albendazole and azithromycin was 80.3% and 93% respectively. Reported
coverage for praziquantel was not available.2.2 Survey sampling methodology
The sampling methodology was a population based 30- cluster survey as recommended by the
WHO LF manual and described in detail by Worrell and Mathieu (Worrell and Mathieu 2012).
Clusters were selected by Probability Proportional to Estimated Size (PPES) and in each cluster,
10 houses were selected using the improved EPI walk(Worrell and Mathieu 2012). The first step
was a census of all members living in the selected household including age, gender, and whether
or not they participated in the MDA. If the one or more of the persons in the household were not
present, the parents or other family member served as a proxy. One random member of the each
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household over the age of 14 was chosen to take the KAP survey. No alternates were selected if
the person was not present at the time of the survey
2.3 Questionnaires
A MDA coverage and knowledge attitudes, and practices (KAP) survey were administered in
each household selected via the sampling procedure discussed above. Survey questions were
open ended, but included answers that the authors anticipated would be most mentioned. For
most questions, multiple answers were possible. The questionnaires were administered in French.
Informed consent forms were included with each questionnaire. The coverage questionnaire
questions included demographics including age and gender, and if they were answering for
themselves or for a family member. The coverage questionnaire also included questions on
participation in the MDA and which type of medication the person received. For children ages 514, they were also asked if they attended school and whether or not they received the medication
at school. The KAP survey gathered information on the participant’s knowledge of the NTD
treatment, and prevention, participation in the MDA, and reasons for non-compliance. For the
KAP survey, questions were included to assess knowledge, attitudes and practices regarding
control of LF, STH, schistosomiasis, and trachoma infections. Further questions included
knowledge of someone in the household of village with signs or symptoms of LF, trachoma, or
schistosomiasis.

Additionally adults answered questions regarding access to sanitation and

improved drinking water sources.
2.6 Interview training
The interviewers were district-level health personnel selected by the Ministry of Health. The
interviewers were not involved in the MDA distribution. The Ministry of Health (MoH) and
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CDC organized a two -day training which included sampling methodology, informed consent
and administering the questionnaire. The training included in class lectures, a role-play exercise
and a one-day practical session.
2.7 Data management and analysis
Data was entered into Epi Info database by a staff member from the MoH in the district
personnel. Data were analyzed using SAS, version 9.2. Treatment coverage was calculated as x/n
where x is the number of persons treated and n is the total amount of persons surveyed. Various
age strata were created based on age (0-13, 14-24, 25-39, 40-59, and greater than 59 years),
gender, and school attendance. Categorical data were compared using the Mantel Haenszel Chi
square test. KAP MDA coverage was calculated as x/n where x is the number of persons treated
and n is the total amount of persons who participated in the KAP survey.
Demographics were calculated using frequencies. For the KAP survey, participation in the MDA
and relationship to gender and age were calculated and tested using Mantel Haenszel Chi square
tests.
2.8 Ethical considerations
The protocol was evaluated by a CDC human subjects review board and was determined to be
exempt from IRB approval because it consisted of a program evaluation. Verbal informed
consent was obtained from participants over 18 years of age. If the person was less than 18 years
old, verbal informed consent was asked from the head of the household or responsible adult. If
the individual was 6-18 years old, a verbal assent was asked of the child in addition to consent by
the representing adult.
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Results
3.2 Household survey
3.2.1 Demographics
There were 1303 respondents for the coverage survey in the Koza district (Table 1). The
median age was 15 years (range 0-110 years) and 52% were female (Table 1). Almost one fifth
were under 5 years old (N=221, 17%). One third of the persons were school age (N=428, 32.9%,
5-14 years).
3.2.2 Treatment coverage
Coverage was defined as having received ivermectin/albendazole , Azithromycin, or
praziquantel during the MDA. Survey coverage for ivermectin/albendazole was 76.9% (CI 7281.9), Azithromycin 86.8% (CI 80.9-92.7). Praziquantel coverage for children 5-14 years was
39.9% (CI 30.7-49.1). There was no significant difference between male and female coverage
for any of the drugs. There was a statistically significant difference for coverage between selfreporting and reporting for others for ivermectin/albendazole OR 2.2 (95% CI 1.6-3.0) and
praziquantel OR 4.2 (95% CI 2.6-6.7) but not for azithromycin OR 0.977 (95% CI 0.69-1.38)
(Figure 1). For those self-reporting, the coverage was 85.6% for Ivermectin/Albendazole, 52%
for Praziquantel, and 86% for Azithromycin(Figure 1). The coverage when someone else was
reporting was 73% for Ivermectin/Albendazole, 20% for Praziquantel, and 84% for
Azithromycin (Figure 1).
3.2.3 Treatment coverage and school attendance
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Praziquantel was only distributed in schools. Children ages 5-14 years old were 269 times more
likely to have taken Praziquantel than children not attending school (p <0.05) Table 2. Of those
that attended school, 21% of parents reporting for their children did not know if they had taken
praziquantel. There was a statistically significant association between drug coverage and
attending school for ivermectin/albendazole and Praqiquantel administered during the June 2011
MDA (Table 2). Coverage for Azithromycin was not statistically associated with school
attendance Cochran mantel haenszel test statistic (p =0.06)
3.3 Knowledge, Attitudes, and Practices (KAP) survey
3.3.1 Demographics
For the KAP survey, 149 individuals were surveyed and 35.8% (N=53) were male (Table 1). The
median age of the respondents was 41 years (range 14-100) (Table1). 3.3.2 Treatment coverage
according to the KAP survey.
Of the adults participating in the KAP survey, 87.2% (95% CI 78.8%-95.5%) reported taking the
each medication during the MDA. Of those who participated in the MDA, 64% (95% CI: 55%73%) were female
3.3.3 Lymphatic filariasis (LF) knowledge
Of those participating in the KAP survey, 44.3% (66/149) of the participants had heard about LF.
Among people who had heard about LF, 32% (21/66) knew at least one symptom (lymphedema
or swelling) (Table 3). A common incorrect symptom mentioned was itching not related to LF
(9%, 6/66) and 21% (14 /66) said they did not know any symptoms of LF. Among people who
had heard about LF, only 4.5% (3/66) knew that it is transmitted by mosquitoes and 34.5% did
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not know how it was transmitted and gave an incorrect responses . For example, 9% of those that
heard of LF incorrectly believed that LF is transmitted through food and/or water . One fourth of
the respondents knew that taking medicine could prevent LF while nearly one third believed
traditional treatment could prevent LF (Table 3).
3.3.4 Soil transmitted helminths (STH) knowledge
Eighty five percent of individuals surveyed had heard of STH but only 52.3% (78/126) reported
that STH can be prevented with medication and fewer than 5.4% knew that good hygiene and
clean food preparation could prevent STH (Table 3).
3.3.5 Schistosomiasis knowledge
Nearly 75% of those surveyed had knowledge of schistosomiasis (Table 3). There was a
significant relationship between gender and having heard of schistosomiasis. Males had 2.7
higher odds of hearing about schistosomiasis compared to females 95%CI (1.06-6.6). Of
individuals who had heard of schistosomiasis 38% (42/109) knew how to treat or prevent
schistosomiasis and 27% (30/109) gave the wrong answer. For example 5% (6/109) thought that
avoiding the sun was a way to prevent or treat schistosomiasis.
3.3.6 Trachoma knowledge
Nearly 70% of individuals surveyed heard of trachoma (Table 3). Of individuals who had heard
of trachoma less than 35% (33/98) knew how to treat or prevent trachoma and 30% (29/98)
replied that traditional treatment was the way to prevent or treat trachoma (Table 3).
For all the neglected tropical diseases targeted by the MDA there was not a significant
relationship between knowledge of the disease and participation in the MDA.
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3.3.7 Knowledge of persons with symptoms
A summary of respondent’s answers about knowing someone in their household or village with
symptoms of trachoma or lympatic filariais is presented in Table 4. Of the 149 respondents, 1112% reported knowing someone with bloody urine and blindness in their households. Trachoma
was the most common disease observed in the village followed by lymphatic filariasis.
Individuals who reported that someone in their household or village had symptoms were not
statistically more likely to have taken the participated in the MDA than individuals who did not
have someone in their household or village with symptoms.
3.3.8 Participation in the mass drug administration according to the KAP questionnaire
Eighty seven percent (129/149) of adult selected for the KAP survey respondents reported that
they had taken all the medication during the MDA campaign. The most common reason cited for
not taking the medication was being out of town at the time of distribution. The second most
common answer was being pregnant or breastfeeding. Of those taking the medicine, 17.2%
(22/149) reported that they experienced side effects. Stomach ache and nausea were the most
common side effects reported (36.5%), followed by dizziness (18.2%), itching (18.2%), and
diarrhea (9%).
3.3.9 Water and sanitation
The source of drinking water for the majority of respondents was 36% river (N=54) and rain
water collection 34%(N=50). Over 25% of respondents used water from a spring (N=40), 9% tap
water (N=14), and 4% bought water (N=6). The majority of the survey population used latrines
as their main form of sanitation 89.2% (N=133). A minority of respondents practiced open
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defecation in the field, river, or a hole in the ground, 7%, 2%, and 1% respectively. There was no
relationship between source of water or sanitation and participation in the MDA.
4. Discussion
MDA guidelines require participant countries to collect and report data concerning the number of
persons treated during MDAs. However, census figures are often inaccurate, making it difficult
to calculate correct coverage rates. In addition reported coverage figures may also be an
overestimation or underestimation of actual coverage. In the Koza district the reported coverage
rates were comparable to coverage survey rates. According to the KAP survey, the coverage for
the MDA was 87%, well above the target 80% threshold established by WHO. Achieving
consistent high levels of coverage greater than 75% is essential for interrupting transmission of
lymphatic filariasis, STH, schistosomiasis, and trachoma. Obtaining accurate data on treatment
coverage is very important for program evaluation. Although the coverage for the Koza district
MDA may be incomplete or inaccurate to evaluate the health impact, evidence from other studies
have demonstrated that MDA is beneficial and reduces parasite morbidity in the targeted
populations (Amazigo, Leak et al. 2012).
Ivermectin/Albendazole and Azithromycin were both above the targeted coverage of 75%.
However, the survey coverage for Praziquantel was lower than expected. The coverage for
Praziquantel, which was only distributed in schools, was much higher for self-reporting than
when one someone else answered. This seems to indicate that the parents were not aware that
Praziquantel was distributed in schools. Although the school based approach has been reported to
be successful for the distribution of drugs in other similar settings it ultimately depends on how
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many children attend school. Children who do not attend school will be left out of the MDA if
this is the only way school age children are targeted.
The coverage survey had several limitations. First, these survey results are based on self-reported
data and may be subject to recall bias. However, studies in Togo reported that 80% of
respondents were able to accurately recall participation in MDA up to one year after the
campaign ended (Worrell and Mathieu 2012). Second, given that parents often served as proxies
for their children and were not present during the actual treatment, the information provided by
the parents may be less reliable than if the information was provided by the children themselves.
In order to maintain successful high treatment coverage it is important to examine the predictors
of non-compliance with treatment. According to the coverage survey, there was no difference in
coverage between males and females or between age groups. For Praziquantel, one significant
predictor of compliance was school attendance. Although the coverage survey did not determine
any predictors of compliance for Ivermectin/Albendazole and Azithromycin (azithromycin), the
coverage was still over 70% for the population living in the Koza district.
The KAP survey did not reveal any significant predictors of compliance with the MDA. In the
Koza district, the knowledge of the diseases targeted for the MDA was very poor. In the Koza
district most participants in the KAP survey did not have knowledge about the diseases or the
purpose of the MDA including etiology, prevention, treatment, transmission, and personal risk.
Even those that had knowledge of the disease were not more likely to have participated in the
MDA than those who did not know about the disease. There was also no relationship between
those who knew someone in their household or village disease symptoms and MDA compliance.
Studies in both Haiti and Indonesia have suggested that knowledge of LF and symptoms,
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especially if seen in the community through photographs were predictors of compliance with the
MDA (Mathieu, Lammie et al. 2004; Krentel, Fischer et al. 2006)It is important to achieve high
levels of coverage in order to interrupt transmission and elimination of diseases targeted by the
MDA. People who do not participate in the MDA could provide a reservoir for the parasites and
maintain transmission after the MDA programs are no longer in place. Although coverage was
high despite low knowledge, for long term sustainability of reduced morbidity and mortality
from NTDS, people in endemic areas need to be aware of ways to prevent re-infection with the
diseases that have been reduced through the MDA. For instance, in Haiti those who knew that
lymphatic filariasis was transmitted by mosquitoes were more likely to participate in the
MDA(Mathieu, Lammie et al. 2004). Educational programs as part of MDA have demonstrated
to increase knowledge of persons and make them aware that avoiding mosquito bites is a way to
prevent LF (Krentel, Fischer et al. 2006).

5. Conclusion

This study stresses the importance of completing a KAP survey in addition to a coverage survey.
Through evaluation of the MDA program we can identify opportunities for improvement of drug
delivery and communication strategies to increase awareness of the diseases and the purpose of
the MDA. Populations living in endemic areas need to be targeted with appropriate health
education messages and appropriate drug delivery strategies. In the American Samoa, a KAP
survey identified barriers in MDA participation for LF including not knowing about the MDA,
and unperceived risk from LF (King, Zielinski-Gutierrez et al. 2011). After educational messages
were targeted to fill in the knowledge gaps, MDA compliance increased from 71% in 2003 to
92.7% in 2004 (King, Zielinski-Gutierrez et al. 2011).
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In the Koza district, those who had knowledge of the disease or knew someone with the disease
were not more likely to participate in the MDA. One possible way to increase coverage could be
to increase health education. In Uganda it has been reported that when health education was
poor, the information about appropriate health behaviors to prevent NTD transmission was
confusing (Parker and Allen 2011). In India, more targeted health messages significantly
increased MDA awareness and coverage(Babu and Kar 2004). Another way to increase coverage
would be to increase the number of MDA campaigns per year since the largest barrier to noncompliance was not being home at the time of the MDA.
Despite the limitations of the coverage and KAP surveys, they are important tools for
assessing treatment coverage and barriers to compliance. Community driven interventions have
been demonstrated to be very successful and have the potential to significantly reduce the
morbidity of LF, schistosomiasis, STH, and ochocerciasis. Evaluating the program can provide
opportunities to modify the MDA program and increase MDA coverage in the Koza district and
other districts in Cameroon.
III. Conclusion

Coverage surveys are an integral part of program evaluation for preventative chemotherapy.
Coverage surveys evaluate the reported coverage determined by drug distributors during the
MDA. Without the coverage surveys the program managers would not know how effective their
efforts are. By completing this coverage survey in the Koza district, program managers know
that they can rely on the reported coverage. Although there were slight differences between the
reported coverage and survey coverage, the results were similar. By knowing that the reported
coverage is reliable, it can save time and effort needed to complete a coverage survey.
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Drug coverage is reported for each individual district for program managers, but is also
reported to the WHO for the entire country. Evaluating coverage for each district on a smaller
scale is a better way for overall program evaluation. The coverage for Ivermectin/Albendazole
was close to the target established by WHO, over 70% for the Koza district. However , when
compared to the coverage for the entire country, Ivermectin/Albendazole coverage is reported to
be less than 50%. According to the World Health Organization preventative chemotherapy
index, the national coverage in 2011 in Cameroon for Ivermectin/Albendazole for treatment of
STH was 46.07%, praziquantel coverage for schistosomiasis 17.19%, and
Ivermectin/Albendazole coverage for LF to be 47.6%(WHO 2012). The coverage for
Ivermectin/Albendazole for STH, and LF was higher in the Koza district, with 70% coverage and
praziquantel coverage was also reported higher in the Koza district at 65% for school age
children. By looking at the MDA program coverage for the entire country, it would appear that
the program is not working equally across the country. By administering the KAP survey,
program evaluators can identify ways to improve the MDA program in a particular area. If the
MDA coverage is high in one district, but low in another program evaluators can look at the
results from the survey to find out what is working and what is not working.
There is a clear association between the burden of NTDs on health and poverty
(Montresor, Gabrielli et al. 2012). Receiving deworming drugs can make a huge difference in
the life of a child as it can impact anemia, improve cognitive and physical development and
school attendance for school age children (Crompton and WHO 2006; Hotez, Molyneux et al.
2006). Mass drug administration of azithromycin has also been associated with reduced risk of
childhood diarrhea and respiratory infections in children (Coles, Seidman et al. 2011; Coles,
Levens et al. 2012).
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The control of NTDs not only positively impacts the health of the targeted populations
but also has other implications. Control of NTDs provides an opportunity to strengthen health
systems at the same time(WHO 2010). Implementation of preventative chemotherapy helps to
train a health care workforce for drug distribution and increases health education(WHO 2010).
These effects on the health care system and capacity building have long term impacts for the
future in often resource poor countries that are endemic for NTDs.
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IV. Tables and Figures for Manuscript
Table 1: Demographics for coverage and KAP surveys.

Survey Demographics
Total N

% Female
(N)

Median Age

Age Range

Coverage
Survey

N=1303

52%
(N=673)

15 years

0-110 years

KAP survey

N=149

62% (N=96)

41 years

14-100 years

Table 2: Relationship between coverage and school attendance for children ages 5-14 years

Coverage for Children who attended school (ages 514)
Ivermectin/Albendazole

Zithromax

Praziquantel

Attended school

92.4 %

89.8%

65.3 %

Did not attend school

79.9 %

83.3 %

0.69 %

Odds Ratio

3.1

1.8

269.3

95% CI

1.7-5.6

1.0-3.1

37.0-1962.4
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Table 3: Knowledge about NTDs from KAP survey questionnaire
Table KAP Results

% of Respondents

N (number of respondents)

Knowledge of LF:
Heard of LF
Symptoms of LF(knew at least 1 symptom)
Transmission of LF
Treatment of LF

44.30%
31.80%
4.50%
23%

N=66
N=21
N=3
N=15

Knowledge of STH:
heard of STH
Transmission of STH
Treatment of STH

84.50%
38%
52.30%

N=126
N=48
N=78

73%
40%

N=109
N=44

68.50%
30%

N=98
N=29

Knowledge of Schistosomiasis:
Heard of Schisto
Treatment of Schisto
Knowledge of Trachoma:
Heard of Trachoma
Treatment of Trachoma
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Table 4: Knowledge of persons with symptoms of NTDs
% of Respondents
Knew someone with symptom

Household

Village

Elephantiasis

6.7 %

13.4%

Hydrocele

7.4 %

27.5%

Bloody Urine

11.4%

8%

Blindness

12%

54.4%

Flies near eyes of children

24.8%

30.9%

Figure 1: Coverage for self- reporting and reporting for others

Coverage by self reporting or reporting for
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Zithromax
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V. Appendix

Appendix 1: Coverage Questionnaire
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Appendix 2: KAP questionnaire
Questionnaire

Enquêteurs |__|__|

Village____________________
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Numéro du ménage |__|__|

Age

|__|__|

Sexe

M

F

Section 1

1. Est-ce que vous avez entendu parler de éléphantiasis?
1
2
8
9

2.

3.

Oui
Non
Ne sais pas
Refuse de répondre

Allez à Section 2

Comment se manifeste éléphantiasis? Encerclez TOUTE(s) réponse(s)
1.
Eléphantiasis
2.
Hydrocèle
3. Autre
7.
(précisez)
8.
Ne sais pas
9.
Refuse de répondre
Comment est-ce qu’on peut attraper éléphantiasis? Encerclez TOUTE(s) réponse(s
1.
Moustiques
2.
Hériter de mes parents / ma famille
3.
Mal esprits / le sorcier
7.
Autre _________ (précisez)
8.
Ne sais pas
9.
Refuse de répondre

4. Comment est-ce qu’on peut prévenir ou traiter l’éléphantiasis? Encerclez TOUTE(s) réponse(s)
1.
2.
3.
4.
5.
6.

Prendre des médicaments
Dormir sous une moustiquaire
Aller a l’hôpital
Nettoyer les alentours de la maison
Chirurgie
Traitement indigène
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7.
8.
9.

Autre _________ (précisez)
Ne sais pas
Refuse de répondre
Section 2

5…Est-ce que vous avez entendu parler des infections par les vers intestinaux?

1.
2.
8.
9.

Oui
Non
Ne sais pas
Refuse de répondre

Allez à Section 3

6…Comment est-ce qu’on peut attraper des infections de vers intestinaux?Encerclez TOUTE(s)
réponse(s)

0.
1.
2.
3.
4.
5.
6.
7.
8.
9.

Manque d’hygiène
Nourriture (pas bien lavée/préparé)
Mouches ou bestioles
Vers à travers la peau de pied
L’eau sale
Ne pas laver les mains
Ne pas utiliser les latrines
Autre ______________________________ (précisez)
Ne sais pas
Refuse de répondre

7…Comment est-ce qu’on peut prévenir ou traiter les infections de vers intestinaux? Encerclez
TOUTE(s) réponse(s)

1.
2.
3.
4.
5.

Prendre médicaments
Laver les mains
Utiliser les latrines
Bien préparer/laver la nourriture
Porter les chaussures
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6.
7.
8.
9.

Traitement indigène
Autre _______(précisez)
Ne sais pas
Refuse de répondre

Section 3

8…Est-ce que vous avez entendu parlez de {mot local} schistosomiase?
1.

Oui

8.a. Comment on peut prévenir/traiter schistosomiase?
Encerclez TOUTE(s) réponse(s)
1.
2.
3.
7.
8.
9.

2.
8.
9.

Prendre médicaments
Eviter nager l’eau
Utiliser les latrines
Autre
______________ (précisez)
Ne sais pas
Refuse de répondre

Non
Ne sais pas
Refuse de répondre

9…Est-ce que vous avez entendu parlez de trachome?

1. Oui
réponse(s)

9.a.Comment on peut prévenir/traiter le trachome? Encerclez TOUTE(s)

1. Laver le visage
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2.
3.
4.
7.
8.
9.

2.
8.
9.

Prendre les médicaments
Utiliser les latrines
Traitement indigène
Autre __________
Ne sais pas
Refuse de répondre

Non
Ne sais pas
Refuse de répondre

10.
La morbidité
Est-ce qu’il y a quelqu’un

Vous connaissez quelqu’un

dans votre ménage qui souffre de :

dans le village qui souffre de :

Eléphantiasis

Oui Non

?

Oui

Non

?

Hydrocèle

Oui Non

?

Oui

Non

?

Urine sanglante

Oui Non

?

Oui Non

?

Aveugle

Oui Non

?

Oui Non

?

Oui Non

?

Oui Non

?

Mouche au tour des yeux des
enfants

11. Est-ce que vous avez pris les médicaments chaque fois ils étaient offerts pendant la dernière
campagne?
1. Oui
2.
3. Non
réponse(s)

11.a Pour quoi vous n’avez pas pris les médicaments ? Encerclez TOUTE(s)

1. Distributeur/infirmier me disait que je ne pouvais pas les prendre
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2.
3.
4.
5.
6.
7.
8.
9.
8. Ne sais pas
9. Refuse de répondre

J’étais enceinte
Je n’étais pas à la maison
J’étais malade
Je ne voulais pas
J’ai peur des symptômes secondaires
Autre __(précisez)
Ne sais pas
Refuse de répondre
Allez à Section 4

12. Vous avez eu des problèmes/effets secondaire après avoir pris les médicaments?

1. Oui

12.Après quel médicament cerclez toute(s) réponse(s)
1. Mectizan/albendazole (oncho/filariose lymphatique)
2. Zithromax (pour le trachome)

Quel était le problème? cerclez toute(s) réponse(s)

0.
1.
2.
3.
4.
5.
6.
10.
11.
12.
7.
8.
9.

Mal à la tête
Fièvre
Vertiges
Nausee
Douleur testiculaire
Démangeaison
Douleur générale
Diarria
Vomissement
fatiguee
Autres _____________________ (précisez)
Ne sais pas
Refuse de répondre

2. Non
8. Ne sais pas
9. Refuse de répondre
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Si non, allez à
Section 4

13. Est-ce que vous avez du payer pour avoir les médicaments ?
1.
Oui
13.a.Combien ? _______
2.
Non
8. Ne sais pas
9. Refuse de répondre
Section 4
14. Quel est la source de l’eau pour votre ménage?
1.
Puits
2. Forage
2.
3.
4.
5.
6.
7.

Source
Rivière (mayo)
Eau vendue dans les bidons
Robinet
L’eau de pluie
Autre __________________________ (précisez)

8. Ne sais pas
9. Refuse de répondre

15 Combien de temps devez-vous marcher pour aller chercher de l’eau pendant la saison
seche
: |__|__|__| (minutes)
16. Où est ce que les membres de vote famille vont faire les selles de l’habitude?
1.
2.
3.
7.

Champ
Latrine
Rivière
Autre ________________________ (précisez)

8. Ne sais pas
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9. Refuse de répondre
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